Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UWN2D CAR-T in Recurrent Glioblastoma
NCT04717999Phase 1Unknown
- Sponsor
- UWELL Biopharma
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- CAR-T Cells, TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of UWN2D CAR-T in glioblastoma (GBM), sponsored by UWELL Biopharma. Primary endpoint: Dose-Limiting Toxicity at 2 years. Status: unknown.
02
Drugs
UWN2D CAR-T
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04717999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717999.